ストックスクリーナーアプリを入手
1.92
5.88%
-0.12
前日終値:
$2.04
開ける：
$1.99
24時間の取引高:
39,021
Relative Volume:
1.33
時価総額：
$10.44M
収益：
-
当期純損益:
$-14.29M
株価収益率:
-0.4812
EPS:
-3.99
ネットキャッシュフロー:
$-12.27M
1週間 パフォーマンス:
-12.33%
1か月 パフォーマンス:
-24.22%
6か月 パフォーマンス:
-26.15%
1年 パフォーマンス:
-69.76%
1日の値動き範囲:
$1.90
$2.0981
1週間の範囲:
$1.90
$2.3379
52週間の値動き範囲:
$1.90
$6.70
Aprea Therapeutics Inc Stock (APRE) Company Profile
名前
Aprea Therapeutics Inc
セクター
電話
215-948-4119
住所
3805 OLD EASTON ROAD, DOYLESTOWN, MA
APRE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.92 | 10.44M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-06-22 | 開始されました | H.C. Wainwright | Neutral |
| 2020-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2019-10-28 | 開始されました | JP Morgan | Neutral |
| 2019-10-28 | 開始されました | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aprea Therapeutics Inc (APRE) 最新ニュース
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MyChesCo
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Brokers Issue Forecasts for APRE FY2025 Earnings - Defense World
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN
What is Wedbush’s Estimate for APRE FY2029 Earnings? - Defense World
APRE stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
APRE stock touches 52-week low at $2.15 amid market challenges - Investing.com India
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics Advances Cancer Trials Amid Financial Progress - TipRanks
Aprea Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
APREA THERAPEUTICS Earnings Results: $APRE Reports Quarterly Earnings - Nasdaq
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo
Aprea Therapeutics (APRE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MyChesCo
MD Anderson to explore Aprea’s WEE1 kinase inhibitor for HNSCC - BioWorld Online
Aprea Therapeutics partners with MD Anderson for cancer study - Investing.com India
Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc) - Marketscreener.com
Aprea Therapeutics partners with MD Anderson for cancer study By Investing.com - Investing.com South Africa
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - The Manila Times
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MSN
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MSN
Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World
Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Ault Global (NYSEAMERICAN:DPW) Enters into Exchange Agreement with Orchid Finance LLC – Converts Outstanding Term Note for Convertible Promissory NoteThe financial landscape of Ault Global, trading under the ticker symbol DPW on the NYSE Amer - Defense World
Aprea Therapeutics Announces Update to Patent Portfolio in DNA Damage Response Cancer TherapeuticsDOYLESTOWN, PA, February 5, 2025 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) provided an update on its existing patent portf - Defense World
FDA Greenlights Aprea Therapeutics' Investigational New Drug Application for Novel Cancer Treatment - MSN
Aprea Therapeutics provides update on existing patent portfolio - Yahoo Finance
Aprea Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com South Africa
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times
Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034 | DelveInsight - The Globe and Mail
APRE News Today | Why did Aprea Therapeutics stock go up today? - MarketBeat
Aprea Therapeutics Discloses Unaudited Financials and Updates Corporate PresentationAprea Therapeutics, Inc. recently released an updated corporate presentation, alongside disclosing financial information as of December 31, 2024. The company shared - Defense World
StockNews.com Begins Coverage on SenesTech (NASDAQ:SNES) - Defense World
H.C. Wainwright sets target on Aprea stock, Buy rating on clinical update - MSN
HC Wainwright Reiterates Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering - Yahoo Finance
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MSN
Chronic Lymphocytic Leukemia Therapeutics Market Size in the 7MM is projected to grow during the forecast period 2024-2034 and estimated DelveInsight - The Globe and Mail
Lexicon Appoints Scott Coiante as Chief Financial Officer - The Manila Times
Lexicon Pharmaceuticals Names Veteran Pharma Executive Scott Coiante as New CFO - StockTitan
Aprea Therapeutics Inc (APRE) 財務データ
収益
当期純利益
現金流量
EPS
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):